 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Myriad Genetics, Pharma Mar Explore PGx Strategy for DNA-Damaging Synthetic Alkaloid PM1183
August 01, 2012
Myriad Genetics, Pharma Mar Explore PGx Strategy for DNA-Damaging Synthetic Alkaloid PM1183
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ACLU, PUBPAT Seek to Challenge Patentability of Isolated Genes Before Supreme Court
October 12, 2011 / Pharmacogenomics Reporter - Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo
November 3, 2010 / Pharmacogenomics Reporter - Myriad Prepared to Make Small IP Sacrifice to Aussies in Light of Landmark US Patent Case
October 6, 2010 / Pharmacogenomics Reporter - Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
March 31, 2010 / Pharmacogenomics Reporter